ClinicalTrials.gg
RecruitingNCT07163780HEP-DSUpdated Nov 14, 2025

The Effect of the HEP Approach in Infants With Down Syndrome

An interventional study of HEP Intervention and Traditional Therapy in Down Syndrome (DS), sponsored by Izgi Miray Demirbag. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 4 Months to 12 Months. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Izgi Miray Demirbag · Not applicable, Interventional, and Other

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
4 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Down Syndrome with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Down Syndrome · Turkey.

Planned enrollment
9th of 13
26 · median 34
Started
2025
with 2 others
No phase
13 of 19
1 open now
Registered
15th of 19
by date

Among the 19 studies in Down Syndrome with a site in Turkey, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, and was the 15th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

1 of the 19 studies in Down Syndrome with a site in Turkey is open now.

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 4 Months to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Down Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This study evaluates the effect of the HEP (Homeostasis-Enrichment-Plasticity) approach on motor and sensory development in infants with Down syndrome. Thirty-two infants will receive either HEP or traditional therapy over 12 sessions, and outcomes will be measured using standardized developmental tests.

Read the detailed description

This clinical study will be conducted at a private clinic in Istanbul and will enroll 26 infants with Down syndrome who meet the inclusion criteria. Participants will be recruited through social media and referrals from professionals who follow infants with Down syndrome.

Written informed consent will be obtained from parents after explaining the study's purpose, duration, assessments, and interventions. Demographic, perinatal, natal, and postnatal data will be collected via a "Demographic Information Form." Gross and fine motor skills will be evaluated with Peabody Developmental Motor Scales-2 (PDMS-2), sensory functions with the Infant Sensory Function Test (BDFT), and parents will complete the The Ages and Stages Questionnaires (ASQ) to assess multiple developmental domains. Individual goals will be set using the Goal Attainment Scale (GAS), and social validity will be assessed post-intervention via a parent questionnaire.

The intervention group will receive 12 sessions (once a week, 45 minutes each) of HEP therapy, delivered by a physiotherapist experienced in the HEP approach. The control group will receive 12 sessions of traditional therapy administered by an experienced pediatric rehabilitation physiotherapist.

03

Conditions studied

  • Down Syndrome (DS)

Browse trials for

Keywords

  • Down Syndrome
  • Infants
  • Early Intervention
  • Neuroplasticity
  • Environmental Enrichment
04

Who can participate

Ages eligible
4 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be between 4 and 12 months old
  • Must have been diagnosed with Down Syndrome
  • Must not be at any neurological risk
  • Parent must agree to participate regularly in the study process

Exclusion criteria

Exclusion Criteria:

  • History of intraventricular hemorrhage (Grade III or IV)
  • Major vision or hearing impairment
  • History of febrile convulsion
  • Medical conditions (e.g., oxygen dependence) that prevent active participation in the study
  • Participation in other experimental rehabilitation studies
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    HEP Intervention

    Participants will receive 12 sessions of HEP therapy, once per week, 45 minutes each.

    Behavioral: HEP Intervention

  • Active comparator
    Traditional Therapy

    Participants will receive 12 sessions of traditional therapy, once per week, 45 minutes each.

    Behavioral: Traditional Therapy

Interventions

  • BehavioralHEP Intervention

    This intervention is administered to the HEP Intervention arm. The HEP approach, which includes intervention, is a child-centered, family-based early intervention approach based on the principles of enriched environment and plasticity, emphasizing the importance of homeostasis. It is based on theories that argue that development occurs as a result of the dynamic interaction between the environment, time, task, and individual (Ecological Theory, Dynamic Systems Theory, Perception-Action Theory, Neuronal Group Selection Theory, and the Person-Environment-Occupation Model). Hypotheses for intervention are generated based on a comprehensive assessment of these four fundamental factors (environment, time, task, and individual), and 10 core principles derived from environmental enrichment studies are applied with the guidance of ecological models.

  • BehavioralTraditional Therapy

    Participants in this arm will receive conventional pediatric therapy, consisting of 12 weekly sessions of 45 minutes each. Sessions will focus on standard motor and sensory development exercises, delivered by a physical therapist experienced in pediatric rehabilitation.

06

What researchers measure

Primary outcomes

  1. Peabody Developmental Motor Scales-2 (PDMS-2)

    The PDMS-2 is a scale used to identify motor developmental delays in children aged 0-6 and to determine motor skill levels and individual needs. The PDMS-2 consists of two main sections: gross motor and fine motor, and 249 items. The gross motor section consists of reflexes, balance, locomotion, and object manipulation, while the fine motor section consists of comprehension and visual-motor integration. A score of 2 is given if the child's performance is within the desired level, 1 if it is similar to the desired level, and 0 if it is not. To determine the risk and level of developmental delay, gross motor skills, fine motor skills, and general motor development are categorized as "very low, low, below average, average, above average, high, and very high," using age-appropriate normative ranges in the test manual.

    Time frame: Pre-intervention and 12-week post-intervention.

Secondary outcomes

  1. Test of Sensory Functions in Infants (TSFI)

    Developed to assess sensory responsiveness, this test consists of five subsections and 24 items, and takes 20 minutes to administer. The test subsections include tactile deep pressure response, adaptive motor functions, visual-tactile integration, oculomotor control, and vestibular stimulus response. This test is suitable for evaluating at-risk groups for sensory processing disorders, such as infants with developmental delays. Based on their score, the infant is assessed as normal, at-risk, or impaired in terms of sensory processing. A higher score indicates better sensory processing.

    Time frame: Pre-intervention and 12-week post-intervention.

  2. The Ages and Stages Questionnaires (ASQ)

    The ASQ is a developmental screening test that allows parents to assess a child's development. The questionnaires consist of three sections: demographic questions, a 30-question section about the child's development, and seven open-ended questions. The 30 questions addressing the child's development cover the areas of communication, fine motor development, gross motor development, problem-solving, and personal and social development, with each section consisting of six questions.

    Time frame: Pre-intervention and 12-week post-intervention.

Other outcomes

  1. The Goal Attainment Scale (GAS)

    The Goal Attainment Scale (GAS) is the most commonly recommended goal-setting methodology for measuring change during and after intervention in clinical and research applications. The GAS, which assesses the child's achievement of individual goals established with parents at the beginning of the intervention, is a reliable tool for children with developmental challenges and provides subjective information about the child's needs. The GAS has a rating scale of "-2" to "+2."

    Time frame: Pre-intervention and 12-week post-intervention.

07

Study locations

1 of 1 sites recruiting
  • Sense On
    Istanbul, Beykoz 34810, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant consent does not include sharing data with other researchers. Data will be maintained in strict confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2025, 3 months after the start.

Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 33. This study's planned 3 months is below that.

Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 9, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Dec 3, 2025
CompletionEst.
Dec 3, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163780
Lead sponsor
Izgi Miray Demirbag
Responsible party
Izgi Miray Demirbag (Physiotherapist, Medipol University) — Sponsor-investigator
First posted
Sep 9, 2025
Start date
Sep 3, 2025
Primary completion
Dec 3, 2025 (estimated)
Completion
Dec 3, 2025 (estimated)
Last update
Nov 14, 2025

Study contacts

İzgi Miray Demirbağ, Physiotherapist
Contact
izgimiray@hotmail.com
+905516626550
Gamze Cagla Sırma, Physiotherapist
Contact
cagladirgen@hotmail.com
+905454470067
Aymen Balıkcı, Dr. Physiotherapist
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion